ABSTRACT
Background: In children with cancer and high risk febrile neutropenia (HRFN), the initial empirical treatment used in our hospital for 5 years includes the association of Cloxacillin + Ceftazidime + Amikacin. There is no chilean literature that reviews the effectiveness of this therapy. Objective: Evalúate the clinical and microbiological effectiveness of this associated therapy in children with HRFN. Method: A prospective-descriptive study evaluating children with HRFN admitted at Hospital Luis Calvo Mackenna between January 2005-August 2006. Results: 100 HRFN episodes were evaluated. In 48 percent of cases, the antimicrobial treatment was considered effective, whereas in 52 percent of episodes the therapy required modifications (15 percent cases within the first 72 hours). The most frequent diagnoses were fever without clinical focus (51 percent) and sepsis (13 percent). 36 percent had microbiological identification and the most frequently isolated bacteria were Escherichia coli (9 percent) and Staphylococcus aureus (9 percent). Conclusions: A favorable answer with the initial empirical therapy was obtained for 48 percent of cases; meanwhile in the remaining episodes, 28 percent required antibiotics modifications without justification. This fact remarks the importance of following the established guidelines for antimicrobial treatment modification in these patients.
Introducción: En los niños con cáncer y netropenia febril (NF) de alto riesgo, se utiliza en nuestro centro hace 5 años, como esquema empírico inicial, la asociación de ceftazidima-amikacina-cloxacilina. No hay literatura nacional que analice la eficacia de este esquema. Objetivo: Evaluar la eficacia clínica y microbiológica de la asociación de ceftazidima, amikacina y cloxacilina en niños con NF de alto riesgo. Método: Protocolo descriptivo, prospectivo. Evaluar niños con NF de alto riesgo hospitalizados en el HLCM entre enero 2005 y agosto 2006. Resultados: 100 episodios de NF de alto riesgo. El tratamiento antimicrobiano fue considerado eficaz en 48 por ciento de los casos, y requirió ajustes en 52 por ciento de los casos. En 13 por ciento se cambia tratamiento sin justificación y en 15 por ciento se realiza antes de 72 horas de iniciado el tratamiento antimicrobiano. Foco mßs frecuente fue: ausencia de foco clínico 51 por ciento, presentando sepsis 13 por ciento de los niños. Hubo identificación microbiológica en 36 por ciento, microorganismos mßs frecuentemente aislados Echerichia coli (9 por ciento) y Staphylococcus aureus (9 por ciento). Conclusiones: Se obtuvo una respuesta favorable de 48 por ciento con el esquema antimicrobiano empírico inicial, de el 52 por ciento restante, en un 28 por ciento se efectúan cambios de antibióticos no justificados, esto recalca la importancia de seguir las pautas ya establecidas para cambio de esquema antimicrobiano en estos pacientes.
Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Anti-Bacterial Agents/therapeutic use , Fever/drug therapy , Bacterial Infections/drug therapy , Neoplasms/complications , Neutropenia/drug therapy , Clinical Evolution , Drug Therapy, Combination , Escherichia coli/isolation & purification , Fever/microbiology , Neutropenia/microbiology , Prospective Studies , Staphylococcus aureus/isolation & purification , Time Factors , Treatment OutcomeABSTRACT
Background: Type 1 diabetes mellitus (DM1) is a disease of increasing incidence among children. The time elapsed between the beginning of symptoms and the diagnosis of the disease is, in most cases, very extended. Aim: To report the clinical picture at onset and laboratory features of children with DM1. Material and methods: Retrospective review of all medical records of patients admitted to the hospital with a DM1 of recent onset. Results: Sixty three males aged 95±47 months and 34 females aged 109±51 months, were studied. Males were significantly younger than females (p <0.05). The lapse between symptoms onset and the diagnosis of the disease was longer in girls than in boys (46±46 and 26±26 days respectively, p <0.02). There was an inverse correlation between plasma glucose and the lapse between symptoms onset and the diagnosis of disease. The most common clinical picture of the disease was the classical symptoms of diabetes (polyuria, polydipsia, weight loss), in 60 percent of cases. Thirty seven percent had developed ketoacidosis at the time of the diagnosis. Ketoacidosis was more common between 1988 and 1995, as compared with the period 1996-2003 (50 percent and 28.8 percent, respectively). The onset of symptoms occurred between April and August (Winter in the Southern Hemisphere) in 38 percent of cases. Conclusions: DM1 is a disease of increasing incidence among children, whose diagnosis is delayed, even though symptoms are evident. The lower incidence of ketoacidosis in our patients between 1996 and 2003 is encouraging.